NCT01889641终止不适用
Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique
University Hospital, Strasbourg, France1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2014年2月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Assess serum IL-26 as a biological marker of SLE compared with sera from control subjects
研究概览
简要总结
Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms. Concordant with preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could be a marker of the disease activity and then a potential therapeutic target. In the present study, serum IL 26 level in lupus patients and control will be measured.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •diagnostic of Lupus according to ACR criteria ( four criteria are necessary)
- •age > 18 years old
排除标准
- •treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study
结局指标
主要结局
Assess serum IL-26 as a biological marker of SLE compared with sera from control subjects
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Serum IL 26 as a Marker of Disease Activity in SLESLENCT05161988Assiut University52
招募中
2 期
Safety of Administering Isoniazid to SLE Patients to Prevent TBTuberculosisSystemic Lupus ErythematosusNCT06618573Universitas Padjadjaran60
已完成
2 期
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled TrialSystemic Lupus ErythematosusNCT04077684Peking University People's Hospital152
招募中
不适用
The role of IL-26 in innate and adaptive Immunity of SpondyloarthritisM45.09M07.39DRKS00014672Abteilung für Nephrologie, Klinikum rechts der Isar der TU München170
已完成
2 期
Low-dose Interleukin-2 for Treatment of Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03312335Onur Boyman, MD16